Established tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19‐9 (CA 19‐9) do not have sufficient sensitivity or specificity.7, 8 However, predictive accuracy can be increased by combining these established biomarkers with new innovative ones to create a multimarker panel.9 The gene discussed is CEACAM5; the disease is neoplasm.